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ABSTRACT 
The treatment of juxtapapillary retinal capillary hemangiomas (JRCHs) is still a therapeutic dilemma without established 
guidelines. Because of the location of these hemangiomas on or adjacent to the optic nerve, treatment is difficult and 
complex, especially when JRCHs are located in the papillomacular bundle. This manuscript reviews the clinically relevant 
data on literature regarding the treatment of JRCHs, focusing on novel combined therapies that have shown promising 
results in these lesions. 
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INTRODUCTION 
Juxtapapillary retinal capillary hemangiomas (JRCHs) are 
vascular hamartomas that occur on or adjacent to the 
optic nerve head (1). Although JRCHs can occur 
sporadically as an isolated condition, most occur in 
association with von Hippel–Lindau (VHL) disease, an 
autosomal dominant neoplastic disorder (2). Three 
distinct growth types of JRCHs have been described, 
including the endophytic, exophytic, and sessile forms 
(3). 
The clinical course of the JRCHs is usually progressive and 
difficult to predict. These tumors can start as small 
lesions at the optic disc or in the peripapillary area (most 
commonly on the temporal side of the disc) (1,2) If left 
untreated, JRCHs can grow and cause complications, 
such as exudation, subretinal fluid accumulation, macular 
edema, and exudative retinal detachment, resulting in 
visual deterioration (2-4). Furthermore, glial proliferation 
can lead to epiretinal membrane development or 
tractional retinal detachment. Rarely, these tumors 
regress spontaneously (5). 
Because of the location of these hemangiomas on or 
adjacent to the optic nerve, treatment is very difficult. 
Although definitive treatment guidelines have yet to be 
established, in general, observation is chosen as the 
initial management of JRCHs in asymptomatic patients (6, 
7). The treatment of these lesions should only be 
undertaken if vision is reduced or if there is lesion 
progression. The main goal of the treatment of JRCHs is 
to preserve visual acuity and the visual field without 
destruction of the function of the retina around the 
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tumor. Treatment depends on the size, location and 
clinical manifestations of the hemangioma. In addition, 
juxtapapillary lesion therapies are often recalcitrant to 
treatment and the visual outcome after treatment varies. 
Several treatments have been proposed, such as laser 
photocoagulation, brachytherapy, transpupillary 
thermotherapy, photodynamic therapy (PDT), and 
surgical excision, but none of these treatments has 
proven to be particularly effective in inducing regression 
of the JRCHs (1-4, 6, 7). 
Laser photocoagulation, brachytherapy and 
transpupillary thermoplasty have been shown to be 
effective in the treatment of optic disc hemangiomas, 
but all these approaches are risky and can result in 
permanent scotomas and poor clinical outcome due to 
the posterior location of the tumor and its proximity to 
the optic nerve (7-10). 
More recently, PDT has been reported to be an 
alternative method to treat JRCHs because it enables a 
more selective vascular occlusion and appears to be less 
damaging to the optic disc.(11-14) Intravitreal anti-
vascular endothelial growth factor (anti-VEGF) therapy 
alone or in combination with PDT has been used to treat 
JRCHs cases (15-19). Good results have been reported 
with these combined treatments (18, 19). 
Vitreoretinal surgery can be a valid option when JRCHs 
are associated with epiretinal membrane formation and 
serous or tractional detachment. Further improvement 
of the treatment results of vitreoretinal surgery may be 
achieved by combination with PDT and with/without 
intravitreal anti-VEGF (20, 21). 
This article reviews the current literature on safety and 
efficacy of several options for treatment of JRCHs, 
focusing on new combined treatments. 
 
Anti-angiogenic (anti-VEGF) agents for JRCHs 
Several anti-VEGF agents (Pegaptanib, Bevacizumab, and 
Ranibizumab) have been used extensively for treatment 
of JRCH and have a relatively good safety profile but 
mixed treatment outcomes, suggesting that the general 
efficacy of anti-angiogenic agents in JRCHs is 
uncertain.(15-17) The rationale of anti-VEGF treatment is 
to achieve disease control by decreasing the growth and 
exudation of JRCHs through limiting the contribution of 
VEGF to these processes (22). 
Intravitreal Ranibizumab, as monotherapy every 4 weeks, 
has shown beneficial effects with the smallest lesion with 
less exudation (16). Smaller lesions may have a higher 
rate of cell proliferation, and may be more sensitive to 
anti-angiogenic inhibition. 
In addition, intravitreal anti-VEGF agents seem to have 
the advantage of a decreased potential for retinal 
damage compared with other treatments for JRCH (17). 
Anti-VEGF agents might therefore be considered as an 
alternative treatment for progressive JRCH, especially in 
patients with well-preserved visual acuity and visual field. 
However, the overall results also indicate limitations of 
intravitreal anti-VEGF treatment as monotherapy: first, 
an effective dose required for JRCHs may need to be 
higher than the dose required for the treatment of 
choroidal neovascularization; and second, the route of 
administration through the vitreous may limit the access 
to tumor cells in the interior of a large endophytic lesion 
(22). In conclusion, intravitreal anti-VEGF treatment as 
monotherapy can be an option in particular to treat 
smaller JRCH without visual acuity loss. However, future 
prospective studies with longer follow-up and greater 
numbers of cases are needed to confirm the 
effectiveness of intravitreal anti-VEGF for JRCHs. 
Also, many cases have been reported in which JRCHs 
were treated with systemic administration of the anti-
VEGF (SU5416 and Bevacizumab), with transient 
reduction in exudation but with limited benefit (23, 24). 
Moreover, the systemic treatment could be associated 
with severe side effects that preclude its further use. 
In summary, Wong et al. suggested the following future 
directions for anti-angiogenic therapy: the use of 
systemic anti-VEGF therapy, possibly combined with 
intravitreal therapy, to increase drug access to a large 
vascularized lesion; the targeting of multiple angiogenic 
molecules as suggested by the molecular biology of the 
disease (e.g. other angiogenic molecules upregulated 
with the loss of VHL function, such as platelet-derived 
growth factor (PDGF)); and the delivery of higher and 
more sustained levels of drug as may be affected by 
sustained release drug devices and intraocular gene 
therapy techniques (22). 
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 Figure 1. Algorithm approach of juxtapapillary retinal capillary hemangiomas 
 
Verteporfin photodynamic treatment (PDT) for JRCHs 
In recent years, verteporfin PDT has been reported to be 
an alternative method to induce tumor regression or 
stabilization because it enables a more selective vascular 
occlusion and appears to be less damaging to the optic 
disc than laser photocoagulation (11-14). In particular, 
PDT was shown to be effective in causing fibrosis and 
involution of the smaller JRCH. For larger tumors, 
verteporfin may only be activated on the surface of the 
tumor, and the reactive oxygen species may not cause 
closure of deeper tumor vessels (12). 
Photodynamic treatment for JRCH can be effective in 
treating macular edema and subretinal fluid, however, 
this may not translate into improvement in visual acuity 
in all cases. Also, the overall results indicate limitations of 
PDT as monotherapy. One possible major limitation of 
PDT is increased fibrosis with associated progression of 
epiretinal membrane (ERM) . In their series, Aaberg et al. 
theorized that while retinal traction may be an inevitable 
effect of tumor fibrosis following PDT, it might be 
modulated by inducing slower tumor regression using 
smaller repeated treatments (25). Other authors 
suggested different protocol parameters from standard 
to minimize the damage to the neural tissue (14, 21, 26). 
Other complications of PDT are transient optic disc 
edema, retinal vessel occlusion, optic neuropathy, 
vitreous hemorrhage, massive retinal detachment and 
massive subretinal hemorrhage (12, 25-27). 
A larger prospective study is necessary to validate the 
efficacy and safety of PDT for JRCHs, particularly 
concerning the risk of ERM development and other 
complications. Important questions regarding the PDT 
dose modulation, treatment frequency, and number of 
treatments also remain unanswered. In addition, the 
exact reason for sensitivity of the tumor to treatment 
remains to be elucidated. 
By combining anti-VEGF with reduced fluence PDT, the 
outline of the primary angioma can be better delineated 
and may thus reduce the energy and the treatment area, 
thereby minimizing the damage to the neurological 
tissues (18). Recent reports of combined therapy with 
anti-VEGF therapy and PDT have shown promising results 
in these lesions (18,19). 
 
Vitreoretinal surgery for JRCHs 
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Vitreoretinal surgery is still an option to consider for the 
treatment of progressive cases of JRCHs complicated 
with ERM formation, serous or tractional retinal 
detachment of the macula and vitreous hemorrhage 
from large tumors, which leads to a poor visual prognosis 
(6). Surgical excision can be a possible option only when 
tumor has an endophytic growth (28). 
However, the visual recovery following surgery will only 
be maintained if the underlying tumors can be eradicated 
or their growth be interrupted. 
In 2011, Gaudric et al. suggested that 20-gauge 
vitreoretinal surgery may be preceded or followed by 
conventional laser photocoagulation or PDT (29). 
More recently, the minimally invasive sutureless 
transconjunctival pars plana vitrectomy (especially 25-
gauge) has progressed so much that it has become the 
approach of choice for most vitreoretinal pathologies 
(30). Mariotti et al. reported a case of a progressive 
paramacular JRCH, with a sessile exophytic growth and 
associated with tractional macular detachment, that was 
managed successfully with 25-gauge vitreoretinal 
surgery, followed by two sessions of half-fluence PDT 
(21). After combined treatment, the patient had marked 
regression of the hemangioma, an increase in visual 
acuity, reduction of papillomacular area fluid, and 
macular drying that persisted at the 2 years follow-up 
visit. Some authors suggested the role of vitreoretinal 
surgery as first approach to improve safety and efficacy 
of PDT. Firstly, displacing tumor as more as possible from 
the head of the optic disc may minimize the risk of optic 
neuropathy after PDT. And secondly, removing glial 
proliferation over JRCH could improve penetration of 
Vysudine in inner part of tumor. However, more studies 
are necessary to validate these theories. 
Fong et al. reported a case of an inferotemporal JRCH 
associated with tractional detachment of the macula that 
underwent successful combined therapy with intravitreal 
ranibizumab injection and PDT one week before 
vitreoretinal surgery (20). 
In similar cases, combining therapy of PDT and 
intravitreal anti-VEGF one week before surgery may be 
useful in reducing the macular edema and the risk of 
retinal cyst rupture during peeling procedure. In 
addition, pre-operative anti-VEGF agents may reduce 
tumor vascularization and intraoperative bleeding (20). 
CONCLUSION 
The treatment of JRCHs remains controversial. Because 
of the location of these hemangiomas on or adjacent to 
the optic nerve, treatment is difficult and complex. In 
addition, the complexity of performing a prospective 
study in JRCHs has been a major barrier to date. 
Several small case series have been reported that 
demonstrate the inconstant clinical course and 
treatment outcomes of these patients. In general, data 
presented in these studies suggest that monotherapies 
with anti-angiogenic agents or with PDT are inadequate 
to treat JRCHs, especially for larger and/or complicated 
lesions. In addition, the exact reason for responsiveness 
of the tumor to several treatments remains to be 
elucidated. 
More recently, case reports with combined therapies 
(PDT plus anti-VEGF; vitreoretinal surgery plus PDT plus 
anti-VEGF) have shown promising results in these lesions. 
A more systematic investigation would support the 
perceived importance of these combined therapies in the 
management of JRCHs. 
According to data in literature, we propose a decision 
tree summarizing recommended approach to the 
treatment of JRCHs. (Figure 1) However; future 
prospective studies are needed to verify these 
hypotheses and to determine successful therapeutic 
strategies for JRCHs. 
New insights into the underlying mechanisms of tumor 
formation and greater knowledge of the natural history 
of the eye disease in VHL disease should lead to 
improved future treatments. In addition, an improved 
genetic and molecular understanding of how VHL 
dysfunction results in ocular disease and the 
development of an animal model for ocular VHL disease 
will be the next substantive steps forward in the 
generation of new therapies for JRCHs (22). 
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